Alkermes' Q3 Proprietary Sales Soar 18%
The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...
El Paso healthcare providers explore Vivitrol as a less known addiction treatment
Taking the first step to start addiction treatment is an uphill battle, but what can prove to be harder is keeping on a regimen that works.
Alkermes upgraded to Buy from Hold at Stifel
Stifel analyst Paul Matteis upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. Published first on TheFly ...
Alkermes (NASDAQ:ALKS) Price Target Cut to $30.00
Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...
Nasdaq14d
Alkermes's Earnings: A Preview
Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating ...
Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Expect
Alkermes PLC (NASDAQ:ALKS) is set to release its Q3 2024 earnings on Oct 24, 2024. The consensus estimate for Q3 2024 revenue ...
ETF Daily News11d
Alkermes (NASDAQ:ALKS) Rating Reiterated by Piper Sandler
Alkermes (NASDAQ:ALKS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Piper ...
PR Newswire13d
Alkermes plc Reports Third Quarter 2024 Financial Results
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on ...